WO2009097270A3 - Method of determining breast cancer risk - Google Patents

Method of determining breast cancer risk Download PDF

Info

Publication number
WO2009097270A3
WO2009097270A3 PCT/US2009/032113 US2009032113W WO2009097270A3 WO 2009097270 A3 WO2009097270 A3 WO 2009097270A3 US 2009032113 W US2009032113 W US 2009032113W WO 2009097270 A3 WO2009097270 A3 WO 2009097270A3
Authority
WO
WIPO (PCT)
Prior art keywords
breast cancer
screening
provides
developing breast
risk
Prior art date
Application number
PCT/US2009/032113
Other languages
French (fr)
Other versions
WO2009097270A2 (en
Inventor
Albert Mark Gold
Kenneth Offit
Tomas Kirchhoff
Zhang-Qun Chen
Original Assignee
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services
Memorial Sloan-Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, Memorial Sloan-Kettering Cancer Center filed Critical The United States Of America, As Represented By The Secretary, Department Of Health And Human Services
Publication of WO2009097270A2 publication Critical patent/WO2009097270A2/en
Publication of WO2009097270A3 publication Critical patent/WO2009097270A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention provides methods and reagents related to a chromosomal loci associated with altered risk for developing breast cancer. The method includes screening genomic sequence information for the presence or absence of one or more polymorphism alleles in chromosome 6q22.33 that indicates a lower risk of developing breast cancer in the subject or an increased risk of developing breast cancer in the subject. The invention also provides related machine readable media and methods of screening for a candidate therapeutic compound for breast cancer. The invention also provides an oligonucleotide or set of oligonucleotides that selectively anneal to genomic DNA comprising one, but not both, of the rs2180341, rs6569479, rs6569480, or rs7776136 SNP alleles. The oligonucleotide or set of oligonucleotides can be provided in kits that also include reagents suitable for screening for the presence or absence of one or more polymorphism alleles in genomic sequence information.
PCT/US2009/032113 2008-01-28 2009-01-27 Method of determining breast cancer risk WO2009097270A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2393608P 2008-01-28 2008-01-28
US61/023,936 2008-01-28

Publications (2)

Publication Number Publication Date
WO2009097270A2 WO2009097270A2 (en) 2009-08-06
WO2009097270A3 true WO2009097270A3 (en) 2009-10-15

Family

ID=40600124

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/032113 WO2009097270A2 (en) 2008-01-28 2009-01-27 Method of determining breast cancer risk

Country Status (1)

Country Link
WO (1) WO2009097270A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5394069B2 (en) 2005-11-29 2014-01-22 ケンブリッジ エンタープライズ リミテッド Markers about breast cancer
US11542328B2 (en) 2008-11-14 2023-01-03 The Brigham And Women's Hospital, Inc. Therapeutic and diagnostic methods relating to cancer stem cells
PT3130923T (en) * 2008-11-14 2020-06-17 Brigham & Womens Hospital Inc Therapeutic and diagnostic methods relating to cancer stem cells
AU2010256343B2 (en) 2009-06-01 2014-01-30 Genetic Technologies Limited Methods for breast cancer risk assessment
WO2011095999A1 (en) * 2010-02-05 2011-08-11 Decode Genetics Ehf Genetic variants for predicting risk of breast cancer
US20140329719A1 (en) * 2011-06-16 2014-11-06 Illumina, Inc. Genetic variants for predicting risk of breast cancer
JP6820838B2 (en) 2014-09-30 2021-01-27 ジェネティック テクノロジーズ リミテッド How to assess the risk of developing breast cancer
CN104694664B (en) * 2015-04-13 2015-12-02 玉峰惠仁生物医药科技（北京）有限公司 PALB2 gene susceptible SNP site detection composition
WO2016172764A1 (en) * 2015-04-27 2016-11-03 Peter Maccallum Cancer Institute Breast cancer risk assessment

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GOLD BERT ET AL: "Genome-wide association study provides evidence for a breast cancer risk locus at 6q22-33", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 105, no. 11, March 2008 (2008-03-01), pages 4340 - 4345, XP002527419, ISSN: 0027-8424 *
HUNTER DAVID J ET AL: "A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer", NATURE GENETICS, vol. 39, no. 7, July 2007 (2007-07-01), pages 870 - 874, XP002527417, ISSN: 1061-4036 *
VON ROTZ RUTH C ET AL: "The novel cytosolic RING finger protein dactylidin is up-regulated in brains of patients with Alzheimer's disease", EUROPEAN JOURNAL OF NEUROSCIENCE, vol. 21, no. 5, March 2005 (2005-03-01), pages 1289 - 1298, XP002527416, ISSN: 0953-816X *

Also Published As

Publication number Publication date
WO2009097270A2 (en) 2009-08-06

Similar Documents

Publication Publication Date Title
WO2009097270A3 (en) Method of determining breast cancer risk
Truong et al. Replication of lung cancer susceptibility loci at chromosomes 15q25, 5p15, and 6p21: a pooled analysis from the International Lung Cancer Consortium
Decock et al. Genome-wide promoter methylation analysis in neuroblastoma identifies prognostic methylation biomarkers
MX2010005060A (en) Dna microarray based identification and mapping of balanced translocation breakpoints.
WO2005082110A3 (en) Haplotype markers for diagnosing susceptibility to immunological conditions
Nejman et al. Molecular rules governing de novo methylation in cancer
Smith-Sørensen et al. Frequent promoter hypermethylation of the O6-Methylguanine-DNA Methyltransferase (MGMT) gene in testicular cancer
WO2007146819A3 (en) Methods for identifying and using snp panels
NZ589863A (en) Genetic markers for weight management and methods of use thereof
JP2017533693A (en) Methods and materials for assessing homologous recombination defects
NZ593628A (en) Genetic variants useful for risk assessment of thyroid cancer using rs944289
CA2798657A1 (en) Diagnostic methods involving loss of heterozygosity
WO2007086980A3 (en) Methods of determining the risk of developing coronary artery disease
WO2008147887A8 (en) Methods and kits for linking polymorphic sequences to expanded repeat mutations
NZ612799A (en) Improved method and kit for determining severity and progression of periodontal disease
WO2003070082A3 (en) Association of snps in the comt locus and neighboring loci with schizophrenia, bipolar disorder, breast cancer and colorectal cancer
HK1096127A1 (en) Identifying chromosomal abnormalities in cells obtained from follicular fluid
EP3075865A3 (en) Genetic markers for efficacy of iloperidone in the treatment of psychotic symptoms
WO2004042032A3 (en) Cytogenetic abnormalities that are predictive of response to therapy for chronic lymphocytic leukemia
WO2007140599A8 (en) Assessment of risk for colorectal cancer
DE602006018861D1 (en) FAST COMPARATIVE GENOM HYBRIDIZATION
WO2008018789A3 (en) Methods and means for diagnosing and treatment of osteoarthritis
WO2010046530A8 (en) Methods and uses involving genetic aberrations of nav3 and aberrant expression of multiple genes
WO2009117346A3 (en) System and method for determining the health of a subject using polymorphic risk markers
WO2006099329A3 (en) Method of analyzing breast cancer susceptibility and resistance

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09706454

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09706454

Country of ref document: EP

Kind code of ref document: A2